[Development of liver organoids from NASH model mice and their application to drug discovery]

Nihon Yakurigaku Zasshi. 2021;156(5):275-281. doi: 10.1254/fpj.21027.
[Article in Japanese]


Nonalcoholic steatohepatitis (NASH) is one of the most common causes of chronic liver disease, with the increased prevalence of obesity, type 2 diabetes, and metabolic disorders in recent years. As the disease progresses, it leads to hepatic fibrosis, which may progress to hepatocellular carcinoma, but there is still no cure for severe hepatic fibrosis. Currently, in order to develop drugs for the treatment of NASH, the effects of candidate drugs are evaluated by a long-term administration to mice and rats that are fed a high-fat or methionine-deficient diet to reproduce the pathology of fatty liver and liver fibrosis. Since drug development using these experimental animals is time-consuming and costly, in vitro models that reproduce the pathology of NASH have recently been developing. In this review, we will outline the current issues in the diagnosis and treatment of NASH, and introduce our research for the discovery of early diagnostic markers and the development of new therapeutic agents using liver organoid cultures derived from mouse models of NASH.

Publication types

  • Review

MeSH terms

  • Animals
  • Diabetes Mellitus, Type 2*
  • Diet, High-Fat
  • Disease Models, Animal
  • Drug Discovery
  • Liver
  • Liver Cirrhosis
  • Mice
  • Mice, Inbred C57BL
  • Non-alcoholic Fatty Liver Disease* / drug therapy
  • Non-alcoholic Fatty Liver Disease* / pathology
  • Organoids
  • Rats